<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066741</url>
  </required_header>
  <id_info>
    <org_study_id>HOMEODENT</org_study_id>
    <secondary_id>ET2006-042</secondary_id>
    <nct_id>NCT01066741</nct_id>
  </id_info>
  <brief_title>Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer</brief_title>
  <official_title>Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BOIRON</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the benefit of a mouthwash with a
      phytopharmaceutical preparation, Homeodent®, compared to a mouthwash solution containing
      sodium bicarbonate, for prevention of severe mucositis (grade ≥3, RTOG classification) in
      patients receiving irradiation for oral cavity, oropharynx, hypopharynx or cavum cancer.

      This is a phase III, controlled, randomized, single blind study. The estimated inclusion
      period is approximately 24 months. The number of patients required in this monocentric study
      is 330 (165 per arm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment of oral cavity, oropharynx, hypopharynx, and cavum cancers is external
      radiotherapy. However, one of the associated toxicities is the occurrence of mucositis which
      can be a limiting factor in the treatment (dose reduction or treatment interruption can limit
      patient's survival), patient's quality of life decreases and severe complications can occur.
      The treatment of mucositis is mainly symptomatic; a randomized study has shown a benefit of a
      mouthwash with Benzydamine, a non steroidal anti-inflammatory drug, for patients receiving
      50-Gy radiation. Another study with a lower number of patients has also shown a benefit of
      using a zinc sulfate solution. Boiron laboratories have developed a phytopharmaceutical
      preparation, Homeodent®, which has no secondary effects and which could prevent
      radiation-induced mucositis. This study will evaluate the efficiency of mouthwash with
      Homeodent® in a large randomized trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient recruitment, the planed sample size appears not achievable
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of occurrence of grade ≥ 3 (RTOG classification) mucositis during irradiation (only the first occurrence will be reported)</measure>
    <time_frame>At the end of irradiation period (6 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of grade ≥2 mucositis</measure>
    <time_frame>At the end of irradiation period (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Mycosis and Herpes virus infection</measure>
    <time_frame>At the end of irradiation period (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of use of symptomatic treatment in case of occurrence of mucositis</measure>
    <time_frame>At the end of irradiation period (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and duration of radiation treatment interruption for toxicity</measure>
    <time_frame>At the end of irradiation period (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiation dose, duration of grade ≥3 mucositis, maximum weight loss and maximum level of oral pain in case of grade ≥3 mucositis.</measure>
    <time_frame>during the occurence of grade≥3 mucositis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment tolerance assessed through a satisfaction questionnaire, and evaluation of compliance</measure>
    <time_frame>during medication administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional intake, estimated using caloric intake and the Detsky score, and rate of enteral and/or parenteral nutrition, in case of toxicity during irradiation</measure>
    <time_frame>during the period of toxicity</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of agreement between the radiation oncologist and the stomatologist for the detection of Grade ≥2 (RTOG classification) mucositis</measure>
    <time_frame>At the end of irradiation period (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the cost of severe mucositis treatment</measure>
    <time_frame>during and until the end of severe mucositis treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Oropharynx Cancer</condition>
  <condition>Hypopharynx Cancer</condition>
  <arm_group>
    <arm_group_label>Homeodent®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.4 % Sodium Bicarbonate solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.
In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Homeodent®</intervention_name>
    <description>Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.</description>
    <arm_group_label>Homeodent®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.4% Sodium Bicarbonate solution</intervention_name>
    <description>Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing</description>
    <arm_group_label>1.4 % Sodium Bicarbonate solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient aged ≥ 18 years

          -  ECOG PS ≤ 2

          -  Patient with oral cavity and/or oropharynx and/or hypopharynx and/or cavum epidermoid
             carcinoma, whatever the stage

          -  Patient receiving a minimum radiation dose of 60 Gy

          -  Planned radiotherapy to at least 1/3 of the oral mucosa and/or oropharynx

          -  Mandatory affiliation with a health insurance system

          -  Signed, written informed consent

        Exclusion Criteria:

          -  Previous irradiation to the oral mucosa and/or oropharynx

          -  Pre-existing mucositis

          -  Pregnant or lactating woman (negative serum or urinary pregnancy test for women with
             child-bearing potential)

          -  Patient included in another study including experimental radiotherapy possibly toxic
             to the mucosa

          -  difficult follow up of the patient

          -  patient deprived of civil rights
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal POMMIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard, LYON</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003 Mar;66(3):253-62. Review.</citation>
    <PMID>12742264</PMID>
  </reference>
  <reference>
    <citation>Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck. 2003 Dec;25(12):1057-70. Review.</citation>
    <PMID>14648865</PMID>
  </reference>
  <reference>
    <citation>Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, Pater J; National Cancer Institute of Canada Clinical Trials Group. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck. 2005 May;27(5):421-8.</citation>
    <PMID>15782422</PMID>
  </reference>
  <reference>
    <citation>Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck. 2004 Jan;26(1):77-84. Review.</citation>
    <PMID>14724910</PMID>
  </reference>
  <reference>
    <citation>Lapeyre M, Charra-Brunaud C, Kaminsky MC, Geoffrois L, Dolivet G, Toussaint B, Maire F, Pourel N, Simon M, Marchal C, Bey P. [Management of mucositis following radiotherapy for head and neck cancers]. Cancer Radiother. 2001 Nov;5 Suppl 1:121s-130s. Review. French.</citation>
    <PMID>11797271</PMID>
  </reference>
  <reference>
    <citation>Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2004;(2):CD001973. Review. Update in: Cochrane Database Syst Rev. 2007;(2):CD001973.</citation>
    <PMID>15106165</PMID>
  </reference>
  <reference>
    <citation>Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000978. Review. Update in: Cochrane Database Syst Rev. 2007;(4):CD000978.</citation>
    <PMID>16625538</PMID>
  </reference>
  <reference>
    <citation>Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, Pajak TF, Fleming TR, Henke M, Bourhis J, Rosenthal DI, Junor E, Cmelak A, Sheehan F, Pulliam J, Devitt-Risse P, Fuchs H, Chambers M, O'Sullivan B, Ang KK. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):674-81.</citation>
    <PMID>14967419</PMID>
  </reference>
  <reference>
    <citation>El-Sayed S, Nabid A, Shelley W, Hay J, Balogh J, Gelinas M, MacKenzie R, Read N, Berthelet E, Lau H, Epstein J, Delvecchio P, Ganguly PK, Wong F, Burns P, Tu D, Pater J. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol. 2002 Oct 1;20(19):3956-63.</citation>
    <PMID>12351592</PMID>
  </reference>
  <reference>
    <citation>Dodd MJ, Miaskowski C, Greenspan D, MacPhail L, Shih AS, Shiba G, Facione N, Paul SM. Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt &amp; soda mouthwashes. Cancer Invest. 2003;21(1):21-33.</citation>
    <PMID>12643006</PMID>
  </reference>
  <reference>
    <citation>Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG, Roodenburg JL. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer. 2003 Apr 7;88(7):1012-6.</citation>
    <PMID>12671696</PMID>
  </reference>
  <reference>
    <citation>Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):479-85.</citation>
    <PMID>12243825</PMID>
  </reference>
  <reference>
    <citation>Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J, Payne D, Bayley A, Ringash J, Kim J, Liu FF, Maxymiw W, Sprague S, Cummings BJ. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):9-13.</citation>
    <PMID>12182969</PMID>
  </reference>
  <reference>
    <citation>Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, Senzer NN, Lockhart PB, Gallagher MJ, Peterson DE, Leveque FG. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer. 2001 Aug 15;92(4):875-85.</citation>
    <PMID>11550161</PMID>
  </reference>
  <reference>
    <citation>Ertekin MV, Koç M, Karslioglu I, Sezen O. Zinc sulfate in the prevention of radiation-induced oropharyngeal mucositis: a prospective, placebo-controlled, randomized study. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):167-74.</citation>
    <PMID>14697435</PMID>
  </reference>
  <reference>
    <citation>Maiche AG, Gröhn P, Mäki-Hokkonen H. Effect of chamomile cream and almond ointment on acute radiation skin reaction. Acta Oncol. 1991;30(3):395-6.</citation>
    <PMID>2036252</PMID>
  </reference>
  <reference>
    <citation>Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL, Novotny P, Clemens-Schutjer D, Bartel J, Michalak JC. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer. 1996 Feb 1;77(3):522-5.</citation>
    <PMID>8630960</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidermoid carcinoma</keyword>
  <keyword>Hypopharynx</keyword>
  <keyword>Oropharynx</keyword>
  <keyword>Oral cavity</keyword>
  <keyword>Oral mucosa</keyword>
  <keyword>Cavum</keyword>
  <keyword>Severe Oral mucositis</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Phytotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

